Dohj LLC Sells 2,407 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Dohj LLC reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 59.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,667 shares of the medical research company’s stock after selling 2,407 shares during the period. Dohj LLC’s holdings in IQVIA were worth $422,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Jag Capital Management LLC lifted its position in shares of IQVIA by 0.4% during the 4th quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company’s stock valued at $2,638,000 after buying an additional 49 shares in the last quarter. Laurel Wealth Advisors LLC lifted its position in shares of IQVIA by 1.1% during the 3rd quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company’s stock valued at $927,000 after buying an additional 50 shares in the last quarter. Raleigh Capital Management Inc. lifted its position in shares of IQVIA by 4.5% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,157 shares of the medical research company’s stock valued at $268,000 after buying an additional 50 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its position in shares of IQVIA by 1.6% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock valued at $702,000 after buying an additional 56 shares in the last quarter. Finally, Greenleaf Trust lifted its position in shares of IQVIA by 1.9% during the 4th quarter. Greenleaf Trust now owns 3,154 shares of the medical research company’s stock valued at $730,000 after buying an additional 58 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Friday, June 21st. The Goldman Sachs Group assumed coverage on IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price target on the stock. Truist Financial lowered their price target on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a report on Friday, May 3rd. Evercore ISI reduced their price objective on IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a research note on Friday, May 3rd. Finally, Robert W. Baird reduced their price objective on IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a research note on Friday, May 3rd. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $258.40.

IQVIA Trading Up 0.7 %

Shares of NYSE IQV traded up $1.57 during trading hours on Thursday, hitting $212.75. 942,715 shares of the company traded hands, compared to its average volume of 1,027,411. The company’s 50 day moving average price is $224.55 and its 200 day moving average price is $230.21. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. The stock has a market capitalization of $38.76 billion, a price-to-earnings ratio of 29.06, a price-to-earnings-growth ratio of 1.93 and a beta of 1.53.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The company had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.